Jefferies analyst Anthony Petrone started ViewRay with a Buy rating and $12 price target. The analyst believes the company is best positioned to capture early MR-linac adoption given its first mover advantage and growing body of clinical evidence. He believes ViewRay’s MRIdian has competitive advantages over Elekta’s MR-linac system.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.